CCI 15106

Drug Profile

CCI 15106

Alternative Names: CCI15106

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic obstructive pulmonary disease

Most Recent Events

  • 14 Aug 2017 GlaxoSmithKline terminates a phase I trial as these will be conducted with the new formulation in Chronic obstructive pulmonary disease in United Kingdom before August 2017 (NCT03243760)
  • 13 Jul 2017 Phase-I clinical trials in Chronic obstructive pulmonary disease in United Kingdom (Inhalation, Powder) (NCT03235726)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top